Enveric Biosciences Inc. announced that its Board of Directors has authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury $(DAT)$ strategy opportunities. These opportunities will be subject to further review and approval by the full Board. The company stated that this initiative aims to enhance shareholder value and support long-term growth, while maintaining a focus on advancing its core biotechnology programs. Further updates will be provided as developments occur.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251014229096) on October 14, 2025, and is solely responsible for the information contained therein.
Comments